Evidence map›Paper›PMID 42079104›Full record

ArticlebioRxiv : the preprint server for biology2026

Predictive Cellular Signatures from Live Human Motor Neurons Distinguish TDP-43 ALS and Enable ALS Subtype Stratification.

Julia Kaye, Naufa Amirani, Úna Chan, Noura Al Bistami, Zohreh Faghihmonzavi, Monika Ahirwar, Reuben Thomas, Wesley Robinson, Edward Vertudes, Krishna Raja and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Julia KayeCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA 94158, USA.ORCID 0000-0001-7442-0882
Naufa AmiraniCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA 94158, USA.
Úna ChanCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA 94158, USA.
Noura Al BistamiCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA 94158, USA.
Zohreh FaghihmonzaviCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA 94158, USA.
Monika AhirwarCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA 94158, USA.
Reuben ThomasGladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA.
Wesley RobinsonCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA 94158, USA.
Edward VertudesCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA 94158, USA.
Krishna RajaCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA 94158, USA.
Mariya BarchCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA 94158, USA.
Drew LinsleyDepartment of Cognitive, Linguistic & Psychological Sciences Brown University, 190 Thayer Street, Providence, RI 02912, USA.
Ana JovicicDepartment of Molecular Biology, Genentech Inc., South San Francisco, CA 94080, USA; Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA.
Steven FinkbeinerCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA 94158, USA.

Funding

Project 4: Cross-species Dissection of Cellular Response to APOE Genotype and AD Pathology Using Single-cell Multi-omicsP01AG073082 · NIA · J. DAVID GLADSTONE INSTITUTES · PI HUANG, YADONG, MUCKE, LENNART · 2021 to 2025
$23.4M
Image Tools for Computational Cellular Barcoding and Automated AnnotationR01LM013617 · NLM · J. DAVID GLADSTONE INSTITUTES · PI FINKBEINER, STEVEN M · 2022 to 2025
$1.6M
NIA NIH HHS P01 AG073082NLM NIH HHS R01 LM013617
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the progressive, rapid deterioration of motor neurons (MNs). Rare mutations in a handful of genes are sufficient to cause ALS; however, 90% of ALS cases are not linked to these genes and their underlying cause remains unknown. Abnormal subcellular distribution, structure or aggregation of the TDP-43 protein are nearly universal hallmarks of the disease, suggesting a shared molecular mechanism across both genetic and sporadic ALS (sALS). However, the heterogeneity of the ALS clinical syndrome suggests that the underlying mechanisms culminating in ALS and TDP-43 pathology may partly differ among individuals and may need to be understood to develop successful therapies that target subgroups of patients. Here, we harnessed the power of machine learning (ML) to begin to decode, in a systematic and unbiased fashion, the cellular signatures of ALS. We used high-content imaging of live, human iPSC-derived motor neurons (iMNs) from ALS patients or gene-edited and gene-corrected TDP-43 mutant lines to train shallow connected ML algorithms (SMLs) and deep convolutional neural networks (DNNs). Our models identified and distinguished mutant and control iMNs with moderately high accuracy. We then used explainability methods to uncover the discriminating cellular signals and found that the strongest ones mapped to the nuclear area, suggesting underlying alterations within the nucleus. We validated this finding by revealing that TDP-43 mutant iMNs display alterations in nucleocytoplasmic shuttling and cellular integrity. Further, a time-interaction ML model uncovered dynamic morphological transitions preceding degeneration, offering a window into early pathogenic events as well as neurodevelopmental changes. Extending our ML pipeline to iMNs with mutations in the ALS gene

Identifiers

PMID42079104
PMCPMC13131495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.